Patents Assigned to Riken
  • Publication number: 20220348852
    Abstract: A culture container (1) having a guide thread (31) and a plurality of cells (32) that is capable of culturing a regenerative hair follicle germ (30), wherein the culture container (1) is equipped with a first recess (10) and a second recess (20) and the second recess (20) has a second bottom (22) where the guide thread (31) can be positioned in the center of an opening (23) and a method for producing a regenerative hair follicle germ that includes a step for aggregating a cell population including epithelial cells (32a) within the second recess (20) of the culture container (1), a step for aggregating a cell population including mesenchymal cells (32b) within the second recess (20), a step for inserting the guide thread (31) into the second recess (20), and a step for culturing the cell population including epithelial cells (32a) and the mesenchymal cells (32b).
    Type: Application
    Filed: June 25, 2020
    Publication date: November 3, 2022
    Applicants: RIKEN, ORGAN TECHNOLOGIES, INC.
    Inventors: Yutaka Mori, Kyosuke Kishimoto, Hisashi Sakai, Ryo Ueno, Takashi Tsuji, Naokazu Okamoto, Miho Ogawa
  • Publication number: 20220348993
    Abstract: A method for detecting a target nucleic acid fragment in a sample, the method including a step of bringing the sample into contact with a gRNA, a Cas protein, and a substrate nucleic acid fragment, in which the Cas protein expresses nuclease activity after forming a complex with the gRNA and the target nucleic acid fragment, the substrate nucleic acid fragment is labeled with a fluorescent substance and a quenching substance, when the substrate nucleic acid fragment is cleaved by the nuclease activity so that the fluorescent substance is separated from the quenching substance, the fluorescent substance emits fluorescence due to excitation light, and the contact is performed in a reaction space having a volume of 10 aL to 100 pL so that when the target nucleic acid fragment is present in the sample, a tripartite complex is formed, the substrate nucleic acid fragment is cleaved, and the fluorescent substance is separated from the quenching substance; and a step of irradiating the fluorescent substance with the
    Type: Application
    Filed: July 6, 2020
    Publication date: November 3, 2022
    Applicant: Riken
    Inventors: Rikiya Watanabe, Osamu Nureki, Hiroshi Nishimasu
  • Publication number: 20220351880
    Abstract: A superconducting wire holding structure includes a holding member made of a first material, a superconducting wire disposed inside the holding member, and a filler made of a second material different from the first material. The superconducting wire includes a substrate, an intermediate layer formed on the substrate, a superconducting layer formed on the intermediate layer, and a first protective layer and a second protective layer that are formed on the superconducting layer. The superconducting layer includes a first portion, a second portion, and a third portion between the first portion and the second portion along a longitudinal direction of the superconducting wire. The first protective layer is formed on the first portion, and the second protective layer is formed on the second portion. The filler is filled between the third portion and the holding member.
    Type: Application
    Filed: August 31, 2020
    Publication date: November 3, 2022
    Applicants: Sumitomo Electric Industries, Ltd., RIKEN, Japan Superconductor Technology, Inc.
    Inventors: Takashi YAMAGUCHI, Kotaro OHKI, Tatsuoki NAGAISHI, Yoshinori YANAGISAWA, Mamoru HAMADA
  • Publication number: 20220344564
    Abstract: A persistent current switch includes a superconducting wire including a substrate and a superconducting layer disposed on the substrate, and a heater. The superconducting wire includes a surface including a first portion and a second portion that are disposed apart from each other along a longitudinal direction of the superconducting wire. The first portion and the second portion face each other. The heater is sandwiched between the first portion and the second portion.
    Type: Application
    Filed: August 31, 2020
    Publication date: October 27, 2022
    Applicants: Sumitomo Electric Industries, Ltd., RIKEN, Japan Superconductor Technology, Inc.
    Inventors: Takashi YAMAGUCHI, Kotaro OHKI, Tatsuoki NAGAISHI, Yoshinori YANAGISAWA, Mamoru HAMADA
  • Patent number: 11473056
    Abstract: The present invention provides a method for producing a retinal progenitor cell, including (1) a first step of subjecting pluripotent stem cells to floating culture in a serum-free medium to form an aggregate of pluripotent stem cells, and (2) a second step of subjecting the aggregate formed in step (1) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway but containing a substance acting on the BMP signal transduction pathway, thereby obtaining an aggregate containing retinal progenitor cells.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: October 18, 2022
    Assignees: SUMITOMO CHEMICAL COMPANY, LIMITED, RIKEN
    Inventors: Tokushige Nakano, Yoshiki Sasai, Chikafumi Ozone
  • Patent number: 11464739
    Abstract: An object is to achieve a nanostructure that has structural stability and temperature responsivity. Provided is a nanostructure which is a hollow body constituted by a wall, the wall including a first region and a second region, the first region being formed from an assembly of a plurality of first amphiphilic molecules containing a hydrophilic block and a hydrophobic block, the second region being formed from an assembly of a plurality of second amphiphilic molecules which are different from the first amphiphilic molecules, the first region being arranged to be in its solid phase at a phase transition temperature at which the second region of the wall transitions from its solid phase to its liquid phase.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: October 11, 2022
    Assignee: RIKEN
    Inventors: Motoki Ueda, Yoshihiro Ito
  • Patent number: 11470722
    Abstract: A current introduction terminal includes a board made of resin. The board has a first face and a second face opposite each other. The board hermetically separates environments of different air pressures from each other. A plurality of through via holes corresponding both to a plurality of metal terminals of a first surface-mount connector to be mounted on the first face and to a plurality of metal terminals of a second surface-mount connector to be mounted on the second face are formed to penetrate between the first and second faces, and then hole parts of the through via holes are filled with resin.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: October 11, 2022
    Assignee: RIKEN
    Inventors: Yuji Matsuda, Takashi Kameshima, Osami Sugata, Toshiaki Tosue
  • Patent number: 11458178
    Abstract: The present invention provides a novel IL-1? and/or IL-6 expression inhibitor and use thereof. The IL-1? and/or IL-6 expression inhibitor in accordance with an aspect of the present invention contains a component derived from alcoholic fermentation lees.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: October 4, 2022
    Assignees: RIKEN, OZEKI CORPORATION
    Inventors: Masanori Yamato, Yosky Kataoka, Yasuhisa Tamura, Satoshi Kume, Toshitaka Minetoki, Kazuhisa Hizume, Satoshi Okazaki, Miyo Hirata, Shinya Okuda, Takayuki Bogaki
  • Publication number: 20220296705
    Abstract: The present invention provides a composition for use in activating innate immunity, comprising an immunostimulant. The present invention also provides a combination use of an immunostimulant and an artificial adjuvant vector cell.
    Type: Application
    Filed: August 7, 2020
    Publication date: September 22, 2022
    Applicant: RIKEN
    Inventors: Shinichiro FUJII, Kanako SHIMIZU
  • Patent number: 11448317
    Abstract: Provided is a side rail 1 having an outer peripheral surface 14, an inner peripheral surface 13, a first axial side surface 11, and a second axial side surface 12 parallel to the first axial side surface 11, in which, a beveled portion 30 is provided between the outer peripheral surface 14 and the second axial side surface 12, the beveled portion 30 is formed in a tapered surface having a diameter gradually decreasing from the first axial side surface 11 toward the second axial side surface in an axial direction; a tapered surface 30a is provided between a first tapered surface portion 30a1 with an angle of 10° or more to the axial direction and a second tapered surface portion 30a2 provided between the first tapered surface portion 30a1 and the outer peripheral surface 14 and having a smaller angle of inclination to the axial direction than that of the first tapered surface portion.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: September 20, 2022
    Assignee: KABUSHIKI KAISHA RIKEN
    Inventors: Yasuhiro Iwata, Hiroshi Shimizu, Yuichiro Takezawa
  • Patent number: 11442181
    Abstract: A gel forming composition for radiation dosimetry, and a high sensitivity and high safety radiation dosimeter using a gel formed from the composition. A gel forming composition for radiation dosimetry comprising a gelator and a compound of Formula (1): (wherein R1 is a hydrogen atom, a halogen atom, an optionally substituted C1-12 alkyl group, etc.; and R2 and R3 are each independently a hydrogen atom, an optionally substituted C1-12 alkyl group, an optionally substituted monovalent C6-12 aromatic group, or R2 and R3 form a 4- to 8-membered ring together with a carbon atom to which R2 and R3 are bonded, and the 4-to 8-membered ring may have 0 to 3 nitrogen atoms, oxygen atoms, or sulfur atoms as a ring atom, provided that R2 and R3 are not simultaneously a hydrogen atom).
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: September 13, 2022
    Assignees: RIKEN, NISSAN CHEMICAL CORPORATION
    Inventors: Takuya Maeyama, Kazuaki Fukasaku, Yasuhiro Ishida, Yoshihiro Kudo
  • Patent number: 11432394
    Abstract: An accelerator (30, 40, 50) includes: a plurality of acceleration cavities (31, 41, 51) having one or two acceleration gaps; and a plurality of first control means (33, 43, 53) provided with respect to each of the plurality of acceleration cavities, each of the plurality of first control means independently generating an oscillating electric field and controlling a motion of an ion beam inside a corresponding acceleration cavity. In addition, M-number of multipole magnets (32, 42, 52) which generate a magnetic field and which control a motion of an ion beam may be provided downstream to N-number of acceleration cavities. The first control means independently controls acceleration voltage and a phase thereof and supplies radiofrequency power. Accordingly, particularly in a front stage of acceleration, a DC beam from an ion generation source can be adiabatically captured.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: August 30, 2022
    Assignee: RIKEN
    Inventors: Hiroyoshi Sakurai, Hiroki Okuno, Yoshiharu Mori, Reiko Fujita, Masatoshi Kawashima
  • Patent number: 11419820
    Abstract: Provided are carotenoid-containing particles having, for preventing exudation of carotenoid at the time of tableting and during storage, a structure in which a carotenoid is dispersed in an agar gel containing a cyclodextrin and/or a plant protein.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: August 23, 2022
    Assignee: Riken Vitamin Co., Ltd.
    Inventors: Kazuyoshi Kondo, Isao Matsuse
  • Patent number: 11421203
    Abstract: The invention relates to a method of producing a retinal pigment epithelial cell from a human pluripotent stem cell, and a method of treating or preventing a retinal disease by using the produced cell. The retinal pigment epithelial cell is prepared by (a) inducing differentiation of a human pluripotent stem cell into a pigment cell by adhesion cultivation of a human pluripotent stem cell in a medium containing a Nodal signal inhibitor and a Wnt signal inhibitor in the absence of a feeder cell to give a culture containing the pigment cell, (b) subjecting the obtained culture to further adhesion culture to give a culture containing a pigment cell colony, and (c) isolating the pigment cell from the obtained culture and culturing the cell to give a retinal pigment epithelial cell.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: August 23, 2022
    Assignee: RIKEN
    Inventors: Masayo Takahashi, Satoshi Okamoto, Noriko Sakai
  • Patent number: 11414429
    Abstract: Provided are 2-(piperidin-1-yl)pyrimidin-4(3H)-ones or pharmaceutically acceptable salts thereof, each characterized by having a 1,8-diazaspiro[4.5]deca-3-ene, 1-oxa-8-azaspiro[4.5]deca-3-ene, 2,8-diazaspiro[4.5]deca-3-ene, 2-oxa-8-azaspiro[4.5]deca-3-ene, 2,9-diazaspiro[5.5]undeca-3-ene, 1-oxa-9-azaspiro[5.5]undeca-3-ene, 1,9-diazaspiro[5.5]undeca-4-ene, or 3,9-diazaspiro[5.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: August 16, 2022
    Assignees: RIKEN, JAPANESE FOUNDATION FOR CANCER RESEARCH, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Minoru Yoshida, Hiroyuki Seimiya, Masayuki Okue, Yoko Yashiroda, Fumiyuki Shirai, Takeshi Tsumura, Yuko Kano, Kenichi Washizuka, Nobuko Yoshimoto, Yasuko Kouda, Takehiro Fukami, Tsubasa Chikada, Takashi Watanabe
  • Publication number: 20220251574
    Abstract: The present invention provides a cell activating the immune system and a pharmaceutical composition containing the cell. According to the present invention, there is provided a mammalian cell having at least one protein selected from the group consisting of E6 protein and E7 protein for early genes of human papillomavirus and a fusion protein of E6 protein and E7 protein, and CD1d protein, wherein the mammalian cell is pulsed with a CD1d ligand. According to the present invention, there are also provided a fusion protein having E7 protein, E6 protein and E7 protein in this order, a nucleic acid encoding the protein and a gene expression vector therefor.
    Type: Application
    Filed: June 12, 2020
    Publication date: August 11, 2022
    Applicant: RIKEN
    Inventors: Shinichiro FUJII, Kanako SHIMIZU
  • Publication number: 20220249572
    Abstract: Provided is a composite comprising a neural retina, a retinal pigment epithelial cell sheet, and a hydrogel.
    Type: Application
    Filed: April 24, 2020
    Publication date: August 11, 2022
    Applicants: Riken, Sumitomo Dainippon Pharma Co., Ltd., Sumitomo Chemical Company, Limited
    Inventors: Yuji Tanaka, Michiko Mandai, Masayo Takahashi, Suguru Yamasaki
  • Patent number: 11389550
    Abstract: Provided is a novel nanoparticle, a contrast agent for magnetic resonance imaging containing the same, and a ligand compound used for production of the nanoparticle. The present invention relates to a nanoparticle including: a metal particle containing iron oxide; and a ligand which is bound to a metal atom on a surface of the metal particle and is represented by formula (3): where m is an integer of 1 to 4, and a broken line represents a coordinate bond with a metal atom on the surface of the metal particle.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: July 19, 2022
    Assignees: RIKEN, NATIONAL INSTITUTES FOR QUANTUM SCIENCE AND TECHNOLOGY
    Inventors: Daigo Miyajima, Toshiaki Takeuchi, Seunghyun Sim, Takuzo Aida, Ichio Aoki
  • Publication number: 20220221594
    Abstract: There is provided a radiation dosimetry gel that is usable in a polymer gel dosimeter having an improved sensitivity and high safety. A radiation dosimetry gel comprising a gelator, and a compound of the following Formula (1): (wherein R1 is a hydrogen atom or a methyl group; m and n are each an integer of 2 to 4; k is 0 or 1; and plurality of R1s and ms are each the same as or different from one another) and a radiation dosimeter comprising the radiation dosimetry gel as a material for radiation dosimetry.
    Type: Application
    Filed: May 18, 2020
    Publication date: July 14, 2022
    Applicants: RIKEN, NISSAN CHEMICAL CORPORATION
    Inventors: Takaoki TAKANASHI, Daniel Antonio SAHADE, Toshimasa HAMADA
  • Patent number: 11382973
    Abstract: The present invention provides an adjuvant that can cause immune activation or particularly T cell immune activation. The present invention provides an adjuvant that can cause particularly antigen-specific immune activation or particularly T cell immune activation.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: July 12, 2022
    Assignee: RIKEN
    Inventors: Shinichiro Fujii, Kanako Shimizu